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A B S T R A C T
Purpose: Lennox–Gastaut syndrome (LGS) is an epileptogenic disorder that arises in childhood and is
typically characterized by multiple seizure types, slow spike-and-wave complexes on EEG and cognitive
impairment. If medical treatment fails, patients can proceed to one of two palliative surgeries, vagus
nerve stimulation (VNS) or corpus callosotomy (CC). Their relative seizure control rates in LGS have not
been well studied. The purpose of this paper is to compare seizure reduction rates between VNS and CC in
LGS using meta-analyses of published data.
Methods: A systematic search of Pubmed, Ovidsp, and Cochrane was performed to ﬁnd articles that met
the following criteria: (1) prospective or retrospective study, (2) at least one patient diagnosed with
Lennox–Gastaut syndrome, and (3) well-deﬁned measure of seizure frequency reduction. Seizure
reduction rates were divided into seizure subtypes, as well as total seizures, and categorized as 100%,
>75%, and >50%. Patient groups were compared using chi-square tests for categorical variables and t-
test for continuous measures. Pooled proportions with 95% conﬁdence interval (95% CI) of seizure
outcomes were estimated for total seizures and seizure subtypes using random effects methods.
Results: 17 VNS and 9 CC studies met the criteria for inclusion. CC had a signiﬁcantly better outcome than
VNS for >50% atonic seizure reduction (80.0% [67.0–90.0%] vs. 54.1% [32.1–75.4%], p < 0.05) and for >75%
atonic seizure reduction (70.0% [48.05–87.0%] vs. 26.3% [5.8–54.7%], p < 0.05). All other seizure types, as
well as total number of seizures, showed no statistically signiﬁcant difference between VNS and CC.
Conclusions: CC may be more beneﬁcial for LGS patients whose predominant disabling seizure type is
atonic. For all other seizure types, VNS offers comparable rates to CC.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Lennox–Gastaut syndrome (LGS) is an epileptogenic disorder
arising in childhood with seizure control a therapeutic chal-
lenge.1,2 Its characteristics can include multiple seizure types, slow
spike-and-wave complexes on EEG and cognitive impairment.3,4
LGS usually persists through adulthood and has a poor prognosis,
despite extensive pharmacological treatment.4,5 The most com-
mon seizure types include tonic, atonic, and atypical absence, but
generalized tonic–clonic (GTC), myoclonic and complex partial
seizures (CPS) can also be present.2,6
When medications fail and there is no resectable seizure focus,
patients can proceed to one of two palliative surgeries, vagus nerve* Corresponding author at: 525 E 68th St., Box 99, New York, NY 10065, USA.
Tel.: +1 212 746 5620; fax: +1 212 746 8947.
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http://dx.doi.org/10.1016/j.seizure.2012.09.014stimulation (VNS) or corpus callosotomy (CC). Although VNS was
approved by the FDA in 1997 for treatment of refractory partial-
onset seizures,7 its efﬁcacy for other seizure-types is recognized.8
CC was ﬁrst introduced as an experimental procedure in 19409 and
has since been accepted in clinical practice to decrease the
frequency and severity of generalized seizures, primarily atonic
seizures,10 although its efﬁcacy in the treatment of other seizure
types has also been recognized.11
VNS is usually recommended ﬁrst because it is a reversible
procedure and is thought to have seizure reduction rates
comparable to those of CC but without the risks of a cranioto-
my.1,12 However, no study has attempted to directly compare
these rates with large samples of LGS patients. Furthermore,
information on the two interventions’ effectiveness for the
different speciﬁc seizure types in LGS is widely scattered. We
hypothesized that CC would prove more effective in reducing
generalized epilepsy types, which include atonic, tonic, GTC, and
myoclonic seizures.vier Ltd. All rights reserved.
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2.1. Search strategy
Three authors (GL, MV, THS) independently performed a
systematic search of PubMed, Ovidsp, and Cochrane for English-
language studies published through December 2010. Search terms
included all combinations of (1) Lennox–Gastaut syndrome, LGS,
Lennox, and (2) VNS, vagal nerve stimulation, vagus nerve
stimulation, callosotomy, corpus callosum, commisurotomy. The
investigators identiﬁed potentially relevant articles by reviewing
abstracts and then thoroughly reviewed references.
2.2. Selection of studies
Inclusion criteria for this meta-analysis consisted of the
following: (1) prospective or retrospective study, (2) case reports
or group study, (3) at least one patient diagnosed with Lennox–
Gastaut syndrome, and (4) well-deﬁned measure of seizure
frequency reduction, either in numbers or ranges, after VNS or
CC. Studies were excluded if seizure frequency data for LGS could not
be extracted from the study population’s data, which sometimes
included other primarily generalized epilepsies. Three authors (GL,
MV, THS) independently reviewed studies that met inclusion criteria
to determine their suitability and quality and unanimously agreed
upon the studies to be included in this meta-analysis.
2.3. Data collection
Data were collected on the following: ﬁrst author, year of study,
retrospective or prospective study, type of treatment, number of LGS
patients in study, gender, age at surgery, age at epilepsy onset,
duration of epilepsy, etiology, VNS parameters, whether VNS
patients had previous CC, partial vs. full CC, time of follow-up,
complications, and seizure reduction rates for each seizure subtype
and all seizures combined (‘‘total seizures’’), categorized as 100%,
>75%, >50%, and <50%. In studies where patients were listed
individually, means and sum totals were used to represent the study
in the ﬁnal analysis. Duplicate data between different studies were
identiﬁed and excluded from the analyses. The corresponding
author of the You et al. paper13was directly contacted regarding the
CC complications in his paper, which he stated were all transient. If
there were multiple follow-up points in a study with decliningFig. 1. Flow chart of numbers of patients, and the data could not be extracted
individually, then the latest follow-up point which maintained a
large proportion of the initial sample was used, as agreed upon by
the authors. Not all data were available in every study.
2.4. Statistical analysis
Characteristics of patients groups (VNS vs. CC) were
compared using chi-square tests for categorical variables and
t-test for continuous measures. p values less than 0.05 were
considered signiﬁcant. Pooled proportions with 95% conﬁdence
interval (95% CI) of seizure outcomes were estimated for total
seizures and seizure subtypes by VNS and CC. To account for
heterogeneity across studies, random effects models were used
for the estimation. The differences between two pooled
proportions were tested by evaluating the overlap of the 95%
CI. The formula in the Wolfe and Hanley paper was followed to
decide signiﬁcance.14 Publication bias was tested with Begg–
Mazumdar bias indicator. Analyses were conducted in StatsDir-
ect version 2.7.8 and STATA version 11. This study was approved
by the Institutional Review Board of the New York Presbyterian-
Weill Cornell Medical Center.
3. Results
3.1. Eligible articles
The literature search yielded 37 VNS and 23 CC abstracts, of
which 13 VNS and 8 CC papers were excluded because they were
review articles, lacked original data, or did not address seizure
frequency (Fig. 1). After careful review and consideration of the
remaining full text articles, 17 VNS studies13,15–30 and 9 CC
studies13,31–38 were included. One study contained data on both
VNS and CC patients independently.13 Additionally, one CC study
was split into groups for the analysis based upon data presenta-
tion.34 All studies were published between 1990 and 2010, of
which 14 were prospective and 12 were retrospective, resulting in
a total of 203 VNS patients and 145 CC patients.
3.2. Group comparisons
VNS patients did not differ signiﬁcantly from CC patients with
respect to gender, mean age at epilepsy surgery, mean age ofstudy selection.
Table 1
Descriptive data reported as mean (standard deviation) (26 studies).
Number of studies
with data available
Vagus nerve stimulation Corpus callosotomy p
Follow-up time (months) 19 16.23 (12.39) 37.76 (24.05) 0.018
Percentage of female 18 0.38 (0.15) 0.30 (0.24) 0.445
Mean age at surgery (years) 21 14.91 (6.98) 11.76 (8.11) 0.357
Duration of epilepsy (years) 15 11.90 (4.47) 7.97 (5.81) 0.169
Percentage of cryptogenic or Idiopathic 15 0.45 (0.22) 0.27 (0.21) 0.194
Age at epilepsy onset (years) 15 1.86 (1.39) 3.17 (3.53) 0.310
G. Lancman et al. / Seizure 22 (2013) 3–8 5seizure onset and mean seizure duration. CC patients had longer
follow-up (p = 0.018) than VNS patients (Table 1).
3.3. VNS
Of the 103 patients whose etiologies were reported, 47 (46%)
had cryptogenic or idiopathic etiology. The other etiologies
included hypoxic–ischemic encephalopathy (14), unspeciﬁed
cerebral malformations (11), tuberous sclerosis (5), lissencephaly
(3), trauma (3), meningoencephalitis (3), encephalitis (2), corpus
callosum agenesis (2), immunization-induced encephalopathy (2),
vitamin b12 deﬁciency (2), and 1 each of unspeciﬁed perinatal
injury, unspeciﬁed CNS infection, prenatal rubella, NF1, measles,
post-radiotherapy encephalopathy, cortical dysplasia, double
cortex syndrome, and microcephaly. 15 had previous corpus
callosotomies.
3.4. VNS parameters
All sixteen studies that reported VNS parameters used 30 s
stimulation (one study did not report VNS parameters). The ‘‘OFF’’
time was 5 min in twelve studies, 3 min in two studies, between 3
and 5 min in one study, and 10 min in one study. 8/9 studies
reported a pulse width of 500 ms while 1/9 used 250 ms. 11/12
studies used an initial output current of 0.25 mA while 1/12 used
0.50 mA. The target output current varied among studies and
within studies but was always between 0.5 mA and 3.0 mA. 7/16Table 2
Data summary comparing VNS and CC for all seizure types. First row is number of stud
intervals.
Seizure type Treatment type Seizure free 
Atonic VNS 7–39
22.8% [6.6–44.9%]
CC 6–44
48.0% [31.0–65.0%
Tonic VNS 5–29
14.2% [4.7–27.8%]
CC No data 
GTC VNS 6–34
13.6% [5.0–25.7%]
CC 5–24
35.0% [9.0–68.0%]
CPS VNS 5–10
15.0% [1.0–42.0%]
CC 3–6
50.4% [9.0–91.4%]
Myoclonic VNS 2–12
46.6% [0.6–98.0%]
CC No data 
Total VNS 15–142
5.2% [2.3–9.2%]
CC 8–124
16.0% [10.0–23.0%
Signiﬁcant differences between VNS and CC are in bold (test using the methods in Wostudies reported trying rapid cycling (7 s ON, 14–18 s OFF) in some
patients if the standard parameters were not effective.
3.5. CC
Of the 81 patients whose etiologies were reported, 25 (31%) had
cryptogenic or idiopathic etiology, while 25 had hypoxic–ischemic
encephalopathy, 15 had encephalitis, 8 had unspeciﬁed cerebral
malformations, 6 had trauma, 1 had prolonged febrile convulsions,
and 1 had an unspeciﬁed intracranial birth injury. 24/129 (19%)
underwent total callosal section while 105 (81%) had partial
callosotomies (ranging from 1/2 to 5/6). Despite increase in
heterogeneity, these groups were all pooled together to be able to
increase sample size.
4. Results of meta analyses
Table 2 shows the number of studies and patients for each
seizure and treatment type and the pooled proportion of seizure
reduction with 95% conﬁdence intervals. There were insufﬁcient
data to analyze outcomes for atypical absence seizures. CC had a
signiﬁcantly better outcome than VNS for >50% atonic seizure
reduction (p < 0.05) and for >75% atonic seizure reduction
(p < 0.05). Although there was also a large mean difference
between CC and VNS for patients who became free of atonic
seizures (48.0% CC vs. 22.8% VNS), this was not found to be
signiﬁcant in the analysis. All other seizure types, as well as totalies–number of patients, second row is the pooled proportion with 95% conﬁdence
>75% reduction >50% reduction
7–39
26.3% [5.8–54.7%]
7–39
54.1% [32.1–75.4%]
]
6–44
70.0% [48.05–87.0%]
8–58
80.0% [67.0–90.0%]
5–29
28.2% [14.6–44.3%]
5–29
34.8% [16.4–55.9%]
No data 3–28
62.0% [29.0–90.0%]
6–34
22.1% [10.9–35.9%]
6–34
44.0% [24.6–64.5%]
5–24
60.1% [42.3–76.6%]
7–63
65.0% [53.6–75.6%]
5–10
40.0% [9.0–77.0%]
5–10
54.0% [19.0–87.0%]
3–6
50.4% [9.0–91.4%]
5–11
56.9% [26.7–84.4%]
No data 2–12
66.0% [40.0–88.0%]
No data 3–37
65.0% [49.0–78.0%]
16–166
28.6% [18.5–40.0%]
17–176
49.3% [37.5–61.2%]
]
6–50
45.2% [26.4–64.9%]
8–124
63.0% [54.0–72.0%]
lfe and Hanley14).
Fig. 2. Forest plots of atonic seizure frequency reduction. VNS and CC are signiﬁcantly different at the >75% (p < 0.05) and >50% (p < 0.05) levels. Note: Squares indicate point
estimates for proportion; horizontal lines indicate 95% CIs; diamonds indicate pooled estimates with 95% CIs.
Fig. 3. Forest plots of total seizures. No differences between VNS and CC are signiﬁcant. Note: Squares indicate point estimates for proportion; horizontal lines indicate 95% CIs;
diamonds indicate pooled estimates with 95% CIs.
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between VNS and CC. Forest plots for atonic seizure reduction and
total seizure reduction are presented in Figs. 2 and 3. Heterogene-
ity between studies was present especially for the pooled
estimation of atonic seizure and total seizures with VNS treatment.
No publication bias was found for the majority of the pooled
analysis.
5. Complications
5.1. VNS
Based on the available data, 5/134 (3.7%) VNS patients had
complications, which included 2 infections at the incision site, 1
vocal cord paralysis, 1 persistent cough, and 1 case of aspiration.
Many patients experienced the standard side effects of VNS
treatment, including hoarseness, coughing, tingling in the throat,
drooling, and voice alteration. These occurred mainly while the
stimulator was on and were considered transient and tolerable.
5.2. CC
Data on CC complications are limited relative to the sample
size; 3/36 (8.3%) suffered complications, including 1 subgaleal ﬂuid
collection, 1 meningitis with prolonged seizures, and 1 respiratory
complication. Some patients experienced transient neurological
deﬁcits, which included akinesia, mutism, hemiparesis, discon-
nection syndrome, and constructional apraxia. All of these
improved rapidly and disappeared a few days after surgery.
6. Discussion
This meta-analysis found that CC is signiﬁcantly more effective
than VNS in achieving a 50% and 75% atonic seizure frequency
reduction in LGS patients. Furthermore, patients in this analysis
were more likely to be completely free of atonic seizures if they
underwent CC (48.0% vs. 22.8% with VNS), although this was not
signiﬁcant.
Tonic, GTC, complex-partial, and myoclonic seizures showed no
statistical difference in response to the two treatments, which may
be due in part to small sample sizes, since patients undergoing CC
showed higher response rates for tonic, GTC, and complex-partial
seizures. Atypical absence seizures, which are particularly difﬁcult
to measure accurately, were not reported often enough in the
literature to conduct any analysis.
The medical literature is rife with debate about the risks and
beneﬁts of CC and VNS for patients with medically intractable
epilepsy and no resectable seizure focus. The general consensus
remains that VNS should be tried ﬁrst because its perceived risk is
lower and it is reversible.1,12 However, this question is especially
complex in LGS patients who have multiple seizure types and
frequent disabling drop attacks. If the primary goal is signiﬁcant
reduction of these atonic drop attacks, then CC appears to be the
better option. However, if other seizure types are present, then VNS
can offer roughly comparable reduction rates to CC.
The risks and side effects of VNS and CC are well-established in
the literature. VNS can cause hoarseness, coughing, tingling in the
throat, and voice alteration during stimulation, in addition to a
small risk of infection after implantation of the device.39 CC carries
the risks of intracranial surgery including infection, hemorrhage,
and stroke, as well as usually transient post-operative neurological
morbidities including lower extremity weakness, disconnection
syndrome, and decreased verbal output.10 In this meta-analysis,
however, serious complications for both procedures were infre-
quent. The often-cited ‘‘disconnection syndrome’’ was only
reported in one CC patient and improved after a few days. Overall,the beneﬁts of both procedures, which are usually a last resort to
long-suffering LGS patient, outweigh the risks.
This study has many limitations. The most important is the
seizure count reliability, as most studies relied on the patient or
caregiver to keep a complete seizure diary and to accurately
identify the different seizure types. In the case of the caregivers,
this necessitated being well-informed about seizure character-
istics and being in constant supervision of the patient. Myoclonic
and atypical absence seizures are especially difﬁcult to count, and
even atonic and tonic seizures can be brief and easy to miss. Since
most tonic seizures in LGS occur during sleep,6 they were likely not
counted in these studies.
Many studies had missing variables or incomplete data. We
were not able to differentiate between the 15 VNS patients who
had previous callosotomy and the rest who did not, nor were we
able to compare the results of symptomatic vs. cryptogenic
etiologies or partial vs. complete CC. Although it is likely that
seizure control would have been better had all patients undergone
a complete callosotomy, the risk of lasting neurological morbidity
may also have increased. Follow-up time was signiﬁcantly greater
in CC patients, which may have affected the analysis because VNS
seizure control tends to improve over time.40,41 In our study, VNS
patients with >12 months of follow-up had a signiﬁcantly greater
50% seizure reduction rate for all seizures combined vs. <12
months of follow-up, while 75% and 100% reduction rates did not
show signiﬁcant differences. Meta-regression analysis showed
that follow-up time and age at surgery were not signiﬁcantly
associated with any seizure outcomes in CC patients (data not
shown).
This study does not address the question of whether there is an
additive effect of CC and VNS, which might argue for performing
both procedures simultaneously to maximize seizure control.
Lastly, the sample size was small for many seizure types. Although
a randomized-controlled trial comparing the two procedures is
impossible, future multi-center studies could prospectively follow
large groups of LGS patients receiving either VNS or CC and
thoroughly chart their seizure outcomes.
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